Loading…
CervoMed Inc. is projected to decline to $2.65 by 2027, a -13% move from its current price of $3.04. CRVO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.92 | $3.04 | $3.16 | -0.03% |
| May 30 | $2.87 | $3.04 | $3.21 | -0.07% |
| May 31 | $2.84 | $3.04 | $3.25 | -0.10% |
| Jun 1 | $2.81 | $3.04 | $3.28 | -0.14% |
| Jun 2 | $2.78 | $3.03 | $3.31 | -0.17% |
| Jun 3 | $2.76 | $3.03 | $3.34 | -0.21% |
| Jun 4 | $2.73 | $3.03 | $3.36 | -0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.73 | $3.03 | $3.36 | -0.24% |
| Week 2 | $2.61 | $3.03 | $3.50 | -0.48% |
| Week 3 | $2.52 | $3.02 | $3.61 | -0.72% |
| Week 4 | $2.45 | $3.01 | $3.71 | -0.96% |
| Week 5 | $2.38 | $3.00 | $3.79 | -1.19% |
| Week 6 | $2.32 | $3.00 | $3.86 | -1.43% |
| Week 7 | $2.27 | $2.99 | $3.93 | -1.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.
Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc.
was founded in 2010 and is headquartered in Boston, Massachusetts.
CervoMed Inc. (CRVO) operates in the Healthcare sector as a clinical-stage biotechnology company. The current price is $3.06, and the company carries a market capitalization of $28.33M with a rank of 4830. These figures place CRVO among smaller-cap biotech listings with a focused pipeline in neurology.
A major floor 28.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.9% below — buyers have tended to step in here.
The nearest ceiling, 32.9% above — a clean break opens room to run.
A major ceiling 139.5% above — clearing it would confirm fresh momentum.
Key CRVO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRVO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.10 | Sell | $3.09 | Sell |
| MA 10 | $3.23 | Sell | $3.22 | Sell |
| MA 20 | $3.50 | Sell | $3.42 | Sell |
| MA 50 | $3.78 | Sell | $3.85 | Sell |
| MA 100 | $4.64 | Sell | $4.65 | Sell |
| MA 200 | $6.53 | Sell | $5.82 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.54 | Neutral |
| Stoch RSI (14) | 35.39 | Neutral |
| CCI (20) | -97.43 | Neutral |
| Williams %R (14) | -85.85 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -23.04 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 14.15 | Buy |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | -0.58 | Sell |
| Ultimate (7,14,28) | 30.93 | Neutral |
| Momentum (10) | -0.73 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 3.01 | Buy |
| ADX (14) | 23.48 | Sell |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is bearish with the RSI at 30, indicating near-term weakness. The stock trades around the 30-day moving average and near-term resistance is seen at $4.04 while support sits at $2.89.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.89 | $3.04 | $4.00 | 0% | Neutral | |
| $2.02 | $2.65 | $3.75 | -13% | Neutral | |
| $2.00 | $2.75 | $4.07 | -10% | Neutral | |
| $1.91 | $2.72 | $4.18 | -11% | Neutral | |
| $2.01 | $2.95 | $4.69 | -3% | Neutral | |
| $2.53 | $3.81 | $6.22 | +25% | Bullish | |
| $2.42 | $3.76 | $6.29 | +24% | Bullish | |
| $2.15 | $3.42 | $5.86 | +13% | Neutral | |
| $2.15 | $3.50 | $6.12 | +15% | Neutral | |
| $2.03 | $3.39 | $6.04 | +12% | Neutral | |
| $2.59 | $4.84 | $9.31 | +59% | Bullish | |
| $3.76 | $8.35 | $17.98 | +175% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.89 | $3.04 | $3.58 | +0.00% |
| June 2026 | $2.47 | $2.93 | $3.58 | -3.52% |
| July 2026 | $2.45 | $2.95 | $3.67 | +0.46% |
| August 2026 | $2.51 | $3.04 | $3.83 | +3.04% |
| September 2026 | $2.42 | $2.95 | $3.77 | -2.76% |
| October 2026 | $2.32 | $2.85 | $3.68 | -3.44% |
| November 2026 | $2.38 | $2.95 | $3.85 | +3.55% |
| December 2026 | $2.44 | $3.04 | $4.00 | +3.02% |
Click any year to see its month-by-month CRVO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CRVO to range from $2.89 to $4.00 through 2026. The $3.04 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The CRVO price prediction for 2027 points to an average of $2.65 (low $2.02, high $3.75) — a potential decline of -13% on today's $3.04. Price action looks broadly range-bound.
In 2028, CRVO is projected to trade between $2.00 and $4.07, averaging $2.75 — a potential decline of -10% from today's $3.04. That is up +3% on the projected 2027 average. A consolidation phase looks the most probable path here.
CervoMed Inc.'s 2029 outlook centres on $2.72, within a $1.91 to $4.18 range. That is -1% versus the projected 2028 average. That marks a -11% change versus current levels. Price action looks broadly range-bound.
By 2030, CRVO could reach as high as $4.69, with a base case around $2.95 and support toward $2.01 — roughly -3% from $3.04. A consolidation phase looks the most probable path here.
Expect CRVO to range from $2.53 to $6.22 through 2031. The $3.81 average target implies a +25% move from current prices. That is up +29% on the projected 2030 average. Momentum favours further upside here.
The CRVO price prediction for 2032 points to an average of $3.76 (low $2.42, high $6.29) — a potential gain of +24% on today's $3.04. Buyers look set to stay in control over this stretch.
In 2033, CRVO is projected to trade between $2.15 and $5.86, averaging $3.42 — a potential gain of +13% from today's $3.04. That is -9% versus the projected 2032 average. Price action looks broadly range-bound.
CervoMed Inc.'s 2034 outlook centres on $3.50, within a $2.15 to $6.12 range. That is up +2% on the projected 2033 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, CRVO could reach as high as $6.04, with a base case around $3.39 and support toward $2.03 — roughly +12% from $3.04. Price action looks broadly range-bound.
Expect CRVO to range from $2.59 to $9.31 through 2040. The $4.84 average target implies a +59% move from current prices. That is up +43% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The CRVO price prediction for 2050 points to an average of $8.35 (low $3.76, high $17.98) — a potential gain of +175% on today's $3.04. Momentum favours further upside here.
Investing $1,000 in CRVO today (≈ 328.947368 CRVO) could be worth
$2,747.92
+$1,747.92 (+175%) by 2050 · US Dollar
Based on the average projected CRVO price of $8.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRVOwould be worth at today's price.
$1,000 invested in CRVO on May 27, 2025 (≈ 125.62814 CRVO) would be worth
$381.91
-$618.09 (-61.8%) today · 0.38× · US Dollar
Based on a CRVO entry price of $7.96 vs. today's $3.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.24 | $938.27 | -6.2% |
| 1 month ago | $3.82 | $795.81 | -20.4% |
| 3 months ago | $4.4 | $690.91 | -30.9% |
| 6 months ago | $9.94 | $305.84 | -69.4% |
| 1 year ago | $7.96 | $381.91 | -61.8% |
| All time (5.0y) ago | $52.5 | $57.9 | -94.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRVO forecast.
Our base-case forecast reaches $6.10 around 2050.
Implied market cap at $6.10: $56.48M
Forecasts show a varied long-run path. In 2026 the avg price is $3.06 with a neutral sentiment and no projected ROI. Through 2031–2032 the average price rises toward $3.83–$3.72 with bullish sentiment and positive ROI (25.2% in 2031 and 21.7% in 2032).
By 2040 the avg price is $4.80 (56.9% ROI) and by 2050 the avg price is $8.12 (165.3% ROI), both labeled bullish. The years 2027–2029 show negative ROI values, with mid-decade volatility (e.g., 2027 -14.1%, 2028 -10.6%, 2029 -13.2%). These are estimates, not guarantees, and actual results may vary.
Tap a question to reveal the answer.
2030 min $1.93, avg $2.88, max $4.66, ROI -5.8%, sentiment NEUTRAL.
The forecast includes negative ROI in 2027 (-14.1%), 2028 (-10.6%), 2029 (-13.2%), and 2030 (-5.8%), followed by positive ROI from 2031 onward (25.2% in 2031 and 21.7% in 2032). Overall, outcomes are uncertain and depend on future developments.
Yes. The max forecast for 2031 is $6.37 and for 2032 is $6.36, with earlier 2030 max at $4.66. Longer-horizon forecasts exceed $5 (e.g., 2040 max $9.48 and 2050 max $17.99).
Current price is $3.06 and market cap is $28.33M.
RSI14 is 30; SMA50 is $3.83; SMA200 is $6.60; 30-day range is $2.32 to $4.03; support is $2.89 and resistance is $4.04.
CervoMed Inc. Community Discussion
0Share your CervoMed Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.